Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. All that said, here are three overhyped stocks that may correct and some you should consider instead.
Texas Instruments (TXN)
One-Month Return: +16%
Headquartered in Dallas, Texas since the 1950s, Texas Instruments (NASDAQ: TXN) is the world’s largest producer of analog semiconductors.
Why Do We Think Twice About TXN?
- Sales were flat over the last two years, indicating it’s failed to expand this cycle
- Expenses have increased as a percentage of revenue over the last five years as its operating margin fell by 14.8 percentage points
- 19.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
At $225.51 per share, Texas Instruments trades at 33.6x forward P/E. To fully understand why you should be careful with TXN, check out our full research report (it’s free).
Jabil (JBL)
One-Month Return: +17.3%
With manufacturing facilities spanning the globe from China to Mexico to the United States, Jabil (NYSE: JBL) provides electronics design, manufacturing, and supply chain solutions to companies across various industries, from healthcare to automotive to cloud computing.
Why Are We Wary of JBL?
- Sales stagnated over the last two years and signal the need for new growth strategies
- Poor free cash flow margin of 3.7% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
Jabil is trading at $307.62 per share, or 22.5x forward P/E. If you’re considering JBL for your portfolio, see our FREE research report to learn more.
10x Genomics (TXG)
One-Month Return: +40.3%
Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ: TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.
Why Should You Sell TXG?
- Sales trends were unexciting over the last two years as its 1.9% annual growth was below the typical healthcare company
- Revenue base of $642.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Push for growth has led to negative returns on capital, signaling value destruction
10x Genomics’s stock price of $25.38 implies a valuation ratio of 5.3x forward price-to-sales. Check out our free in-depth research report to learn more about why TXG doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
